SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bastard C, Tilly H, Lenormand B, Bigorgne C, Boulet D, Kunlin A, Monconduit M, Piguet H. Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. Blood 1992; 79: 252731.
  • 2
    Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002; 28396.
  • 3
    Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999; 1: 1425.
  • 4
    Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008; 26: 96105.
  • 5
    DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 2002; 20: 46438.
  • 6
    Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 272631.
  • 7
    Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol 2001; 2: 35465.
  • 8
    Desablens B, Gardembas M, Delwail V, Le Mevel A, Escoffre-Barbe M, Leprise PY, Briere J, Dutel JL, Harousseau JL, Raphael M, Colombat P. Primary CNS lymphomas: long term results of the GOELAMS LCP 88 trial with a focus on neurological complications among 152 patients. Ann Oncol 1999; 10: 40 (abstract).
  • 9
    Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 571115.
  • 10
    Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998; 41: 61520.
  • 11
    Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes M, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90: 3538.
  • 12
    Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985; 3: 4859.
  • 13
    Pitman SW, Frei E III. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 695701.
  • 14
    Adams JD, Hunter GA. Drug interaction in psoriasis. Australas J Dermatol 1976; 17: 3940.
  • 15
    Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34: 10247.
  • 16
    Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, Van Tellingen O, Borst P, Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 580411.
  • 17
    Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol 1992; 14: 889.
  • 18
    Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26: 2347.
  • 19
    Joerger M, Huitema AD, Van Den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62: 7180.
  • 20
    Karpf DM, Kirkegaard AL, Evans AM, Nation RL, Hayball PJ, Milne RW. Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney. J Pharm Pharmacol 2003; 55: 16416.
  • 21
    Najjar TA, Abou-Auda HS, Ghilzai NM. Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. Cancer Chemother Pharmacol 1998; 42: 4238.
  • 22
    Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 166772.
  • 23
    Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV, Pla JM. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993; 15: 3759.
  • 24
    Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986; 1: 2568.
  • 25
    Titier K, Lagrange F, Pehourcq F, Moore N, Molimard M. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 2002; 24: 5702.
  • 26
    Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 1215.
  • 27
    Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother 1997; 31: 12612.
  • 28
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
  • 29
    Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 15466.
  • 30
    Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan H, Leblond V, Lechat P. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 2006; 58: 62633.
  • 31
    Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 55869.
  • 32
    Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007; 99: 145561.
  • 33
    Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, Van Glabbeke M. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 44838.